Trial Search Results

Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema

This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: placebo for study drug
  • Drug: (RS)2-(3-benzoylphenyl)-propionic acid
  • Other: laboratory biomarker analysis

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Axillary lymph node dissection within the preceding 12 months

Exclusion Criteria:

   - Patients with active cancer

   - Patients with lymphedema

   - Infection or bleeding tendency

   - Patients with medical contraindications to nonsteroidal anti-inflammatory drugs
   (NSAIDs), including history of allergies, know gastrointestinal intolerance

   - Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive
   heart failure, neurological or psychological impairment) that would impair the
   patients' ability to participate

   - Persons not competent to consent

   - Patients on aspirin therapy

   - Minors (< 18 years of age)

   - Pregnant and/or lactating women

   - Males

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting